The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases

Chowdhury, Rasheduzzaman, Yeoh, Kar Kheng, Tian, Ya‐Min, Hillringhaus, Lars, Bagg, Eleanor A, Rose, Nathan R, Leung, Ivanhoe K H, Li, Xuan S +10 more·2011·The EMBO Reports
DOI 10.1038/embor.2011.43

Cited by (1,000)

Items 401–500 of 1,000

  1. The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo
    Johnny Suijker, Hans J. Baelde, Helene Roelofs, Anne‐Marie Cleton-Jansen, Judith V.M.G. Bovée · 2015 · Oncotarget
  2. Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma
    Amir T. Fathi, Brian Vala Nahed, Seth Andrew Wander, Anthony John Iafrate, Darrell R. Borger, Ranliang Hu, Ashraf Thabet, Daniel P. Cahill, Ashley Marie Perry, Christelle P. Joseph et al. · 2016 · The Oncologist
  3. Emerging roles of mitochondrial functions and epigenetic changes in the modulation of stem cell fate
    Chensong Zhang, Yang Meng, Junhong Han · 2024 · Cellular and Molecular Life Sciences
  4. Action at a Distance: Allostery and the Development of Drugs to Target Cancer Cell Metabolism
    Byron DeLaBarre, Jonathan Hurov, Giovanni Cianchetta, Stuart Murray, Lenny Dang · 2014 · Chemistry & Biology
  5. Studies on the Interaction of the Histone Demethylase KDM5B with Tricarboxylic Acid Cycle Intermediates
    Hanna Tarhonskaya, Radosław P. Nowak, C. Johansson, Aleksandra Szykowska, Anthony Tumber, Rebecca L. Hancock, Pauline A. Lang, Emily Flashman, Udo C. T. Oppermann, Christopher John Schofield et al. · 2017 · Journal of Molecular Biology
  6. Oncometabolite D-2-Hydroxyglutarate enhances gene silencing through inhibition of specific H3K36 histone demethylases
    Janke, Ryan, Iavarone, Anthony T, Rine, Jasper · 2017 · eLife
  7. PSPH promotes melanoma growth and metastasis by metabolic deregulation-mediated transcriptional activation of NR4A1
    Rawat, Vipin, Malvi, Parmanand, Della Manna, Deborah, Yang, Eddy S., Bugide, Suresh, Zhang, Xuchen, Gupta, Romi, Wajapeyee, Narendra · 2021 · Oncogene
  8. Inhibition of the Oxygen-Sensing Asparaginyl Hydroxylase Factor Inhibiting Hypoxia-Inducible Factor: A Potential Hypoxia Response Modulating Strategy
    Yue Wu, Zhihong Li, M.A. McDonough, Christopher John Schofield, Xiaojin Zhang · 2021 · Journal of Medicinal Chemistry
  9. Interrogating the Druggability of the 2-Oxoglutarate-Dependent Dioxygenase Target Class by Chemical Proteomics
    Gérard Joberty, Markus Böesche, Jack A. Brown, Dirk Eberhard, Neil S. Garton, P. G. Humphreys, Toby Mathieson, Marcel Muelbaier, Nigel G. Ramsden, Valérie Reader et al. · 2016 · ACS Chemical Biology
  10. Isocitrate dehydrogenase 1–mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress
    Krissie Lenting, Mohammed Khurshed, Tom H. Peeters, Corina N. A. M. van den Heuvel, Sanne A. M. van Lith, Tessa J.J. de Bitter, Wiljan J A J Hendriks, Paul N. Span, Remco Jurriaan Molenaar, Dennis Botman et al. · 2018 · The FASEB Journal
  11. Jumonji domain‐containing protein 6 protein and its role in cancer
    Jing Yang, Siyuan Chen, Yanfei Yang, Xuelei Ma, Bin Shao, Shengyong Yang, Yuquan Wei, Xiawei Wei · 2020 · Cell Proliferation
  12. The PLOD2/succinate axis regulates the epithelial–mesenchymal plasticity and cancer cell stemness
    Yuxin Tong, Yifei Qi, Gaofeng Xiong, Junyan Li, Timothy L. Scott, Jie Chen, Daheng He, Linzhang Li, Chi Wang, Andrew N. Lane et al. · 2023 · Proceedings of the National Academy of Sciences
  13. The malate shuttle detoxifies ammonia in exhausted T cells by producing 2-ketoglutarate
    Nina Weisshaar, Sicong Ma, Yanan Ming, Alaa Madi, Alessa Mieg, Marvin Hering, Ferdinand Zettl, Kerstin Möhr, Nora ten Bosch, Diana Stichling et al. · 2023 · Nature Immunology
  14. IDH mutations in liver cell plasticity and biliary cancer
    Supriya K. Saha, Christine A. Parachoniak, Nabeel M. Bardeesy · 2014 · Cell Cycle
  15. Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor Progression
    Christopher J. Pirozzi, Austin B. Carpenter, Matthew S. Waitkus, Catherine Y. Wang, Huishan Zhu, Landon John Hansen, Lee H. Chen, Paula K. Greer, Jie Feng, Yu Wang et al. · 2017 · Molecular Cancer Research
  16. Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia
    Eytan M. Stein · 2017 · Future Oncology
  17. Landscape of Tumor Suppressor Mutations in Acute Myeloid Leukemia
    Cristina Panuzzo, Elisabetta Signorino, Chiara Calabrese, Muhammad Shahzad Ali, Jessica Petiti, Enrico Bracco, Daniela Cilloni · 2020 · Journal of Clinical Medicine
  18. Human 2-oxoglutarate-dependent oxygenases: nutrient sensors, stress responders, and disease mediators
    Sally C. Fletcher, Mathew L. Coleman · 2020 · Biochemical Society Transactions
  19. IDH2 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in multiple myeloma
    Sha Song, Fan Gao, Qi Li, Qi Su, Xinyun Zhang, Xiaofeng Xue, Zhiming Wang, Chenao Qian, Zhou Jin, Bing-Zong Li et al. · 2021 · Oncogene
  20. IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications
    Kristian A. Choate, Evan P.S. Pratt, Matthew James Jennings, Robert J. Winn, Paul B. Mann · 2024 · Biology
  21. Colorectal Cancer: Pathogenesis and Targeted Therapy
    Jingyuan Li, Jiashu Pan, Lisheng Wang, Guang Ji, Yanqi Dang · 2025 · MedComm
  22. Emerging Role of Linker Histone Variant H1x as a Biomarker with Prognostic Value in Astrocytic Gliomas. A Multivariate Analysis including Trimethylation of H3K9 and H4K20
    Athanasia Sepsa, Georgia Levidou, Antonis N. Gargalionis, Christos Adamopoulos, Anastasia Spyropoulou, Georgia Dalagiorgou, Irene Thymara, Efstathios I. Boviatsis, Marios S. Themistocleous, Kalliopi Petraki et al. · 2015 · PLoS ONE
  23. Gerometabolites: The pseudohypoxic aging side of cancer oncometabolites
    Javier Abel Menéndez, Tomás Alarcón, Jorge Joven · 2014 · Cell Cycle
  24. The role of histone modifications and telomere alterations in the pathogenesis of diffuse gliomas in adults and children
    Julieann C. Lee, David A. Solomon, Tarık Tihan · 2017 · Journal of Neuro-Oncology
  25. Metabolic Regulation of Hypoxia-Inducible Transcription Factors: The Role of Small Molecule Metabolites and Iron
    Peter S. J. Bailey, James A. Nathan · 2018 · Biomedicines
  26. IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment
    Lidia Gatto, Enrico Franceschi, Alicia Tosoni, Vincenzo Di Nunno, Ilaria Maggio, Raffaele Lodi, Alba Ariela Brandes · 2021 · Molecular Diagnosis & Therapy
  27. Metabolic control of cancer cell stemness: Lessons from iPS cells
    Javier Abel Menéndez · 2015 · Cell Cycle
  28. L2hgdh Deficiency Accumulates l -2-Hydroxyglutarate with Progressive Leukoencephalopathy and Neurodegeneration
    Shenghong Ma, Renqiang Sun, Bowen Jiang, Jun Gao, Wanglong Deng, Peng Liu, Ruoyu He, Jing Cui, Minbiao Ji, Wei Yi et al. · 2017 · Molecular and Cellular Biology
  29. 2-hydroxyglutarate inhibits MyoD-mediated differentiation by preventing H3K9 demethylation
    Juan M. Schvartzman, Vincent P. Reuter, Richard P. Koche, Craig B. Thompson · 2019 · Proceedings of the National Academy of Sciences
  30. Lactate Dehydrogenase C Produces S-2-Hydroxyglutarate in Mouse Testis
    Xin Teng, Matthew J. Emmett, Mitchell A. Lazar, Erwin Goldberg, Joshua D. Rabinowitz · 2016 · ACS Chemical Biology
  31. Nitric oxide-driven modifications of lipoic arm inhibit α-ketoacid dehydrogenases
    Gretchen L. Seim, Steven V John, Nicholas L. Arp, Zixiang Fang, David J. Pagliarini, Jing Fan · 2022 · Nature Chemical Biology
  32. TET proteins in cancer: Current ‘state of the art’
    Agnieszka Anna Rawłuszko-Wieczorek, Agnieszka Siera, Paweł Piotr Jagodziński · 2015 · Critical Reviews in Oncology/Hematology
  33. Beyond the Influence of IDH Mutations: Exploring Epigenetic Vulnerabilities in Chondrosarcoma
    Sanne Venneker, Alwine B. Kruisselbrink, Zuzanna Baranski, Ieva Palubeckaitė, Inge H. Briaire‐de Bruijn, Jan Oosting, Pim J. French, Erik H.J. Danen, Judith V.M.G. Bovée · 2020 · Cancers
  34. An l-2-hydroxyglutarate biosensor based on specific transcriptional regulator LhgR
    Zhaoqi Kang, Manman Zhang, Kaiyu Gao, Wen Zhang, Wensi Meng, Yidong Liu, Dan Xiao, Shiting Guo, Cuiqing Ma, Chao Gao et al. · 2021 · Nature Communications
  35. Metabolism–epigenome crosstalk in physiology and diseases
    Shinjiro Hino, Katsuya Nagaoka, Mitsuyoshi Nakao · 2013 · Journal of Human Genetics
  36. Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis
    Shigeo Ohba, Yuichi Hirose · 2016 · Neurologia medico-chirurgica
  37. Tissue-Based Metabolomics to Analyze the Breast Cancer Metabolome
    Jan Budczies, Carsten Denkert · 2016 · Recent results in cancer research/Recent Results in Cancer Research
  38. Quantitative Proteomics Reveals Fundamental Regulatory Differences in Oncogenic HRAS and Isocitrate Dehydrogenase (IDH1) Driven Astrocytoma
    Sophia Doll, Anatoly Urisman, Juan A. Osés-Prieto, David P. Arnott, Alma L. Burlingame · 2016 · Molecular & Cellular Proteomics
  39. Transcriptional and epigenetic mechanisms underlying astrocyte identity
    Maria Angeliki S. Pavlou, Luc Grandbarbe, Noel J. Buckley, Simone P. Niclou, Alessandro Michelucci · 2018 · Progress in Neurobiology
  40. TET1 reprograms the epithelial ovarian cancer epigenome and reveals casein kinase 2α as a therapeutic target
    Lin‐Yu Chen, Rui Huang, Michael WY Chan, Pearlly S. Yan, Tien‐Shuo Huang, Ren‐Chin Wu, Yohan Suryo Rahmanto, Po‐Hsuan Su, Yu‐Chun Weng, Jian‐Liang Chou et al. · 2019 · The Journal of Pathology
  41. Stem Cell Impairment at the Host-Microbiota Interface in Colorectal Cancer
    Marinella Marzano, Bruno Fosso, Elisabetta Piancone, Giuseppe Defazio, Graziano Pesole, Mariangela De Robertis · 2021 · Cancers
  42. The mechanisms of IDH mutations in tumorigenesis
    Dan Ye, Yue Xiong, Kun‐Liang Guan · 2012 · Cell Research
  43. A High-Throughput Mass Spectrometry Assay Coupled with Redox Activity Testing Reduces Artifacts and False Positives in Lysine Demethylase Screening
    Tim J. Wigle, Kerren K. Swinger, John E. Campbell, Michael D. Scholle, John Sherrill, Elizabeth A. Admirand, P. Ann Boriack‐Sjodin, Kevin W. Kuntz, Richard Chesworth, Mikel P. Moyer et al. · 2015 · SLAS DISCOVERY
  44. D-2-Hydroxyglutarate does not mimic all the IDH mutation effects, in particular the reduced etoposide-triggered apoptosis mediated by an alteration in mitochondrial NADH
    Kristell Oizel, Catherine Gratas, Arulraj Nadaradjane, Lisa Oliver, François M. Vallette, Claire Pecqueur · 2015 · Cell Death and Disease
  45. Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutantIDHglioma patients
    Kourosh Jafari‐Khouzani, Franziska Loebel, Wolfgang Bogner, Otto Rapalino, R. Gilberto González, Elizabeth Robins Gerstner, Andrew S. Chi, Tracy T. Batchelor, Bruce Robert Rosen, Jan Unkelbach et al. · 2016 · Neuro-Oncology
  46. Neurological update: gliomas and other primary brain tumours in adults
    Sebastian Brandner, Zane Jaunmuktane · 2017 · Journal of Neurology
  47. Radiation-induced genomic instability, epigenetic mechanisms and the mitochondria: a dysfunctional ménage a trois?
    Janet E. Baulch · 2018 · International Journal of Radiation Biology
  48. Biochemical and structural investigations clarify the substrate selectivity of the 2-oxoglutarate oxygenase JMJD6
    Md. Saiful Islam, M.A. McDonough, Rasheduzzaman Chowdhury, Joseph Gault, Amjad P. Khan, Elisabete Pires, Christopher John Schofield · 2019 · Journal of Biological Chemistry
  49. From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas
    Xueyuan Sun, Şevin Turcan · 2021 · Cells
  50. Oncometabolite Fingerprinting Using Fluorescent Single‐Walled Carbon Nanotubes
    Dean Amir, Adi Hendler‐Neumark, Verena Wulf, Roni Ehrlich, Gili Bisker · 2021 · Advanced Materials Interfaces
  51. Tumor suppressor CEBPA interacts with and inhibits DNMT3A activity
    Xiufei Chen, Wenjie Zhou, Renhua Song, Shuang Liu, Shu Wang, Yujia Chen, Chao Gao, Chenxi He, Jianxiong Xiao, Lei Zhang et al. · 2022 · Science Advances
  52. Tetrazolylhydrazides as Selective Fragment‐Like Inhibitors of the JumonjiC‐Domain‐Containing Histone Demethylase KDM4A
    Nicole Rüger, Martin Roatsch, Thomas Emmrich, Henriette Franz, Roland Schüle, Manfred Jung, Andreas Link · 2015 · ChemMedChem
  53. Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics
    Brunangelo Falini, Paolo Sportoletti, Lorenzo Brunetti, Maria Paola Martelli · 2015 · British Journal of Haematology
  54. Targeting the IDH2 Pathway in Acute Myeloid Leukemia
    Maria L. Amaya, Daniel Aaron Pollyea · 2018 · Clinical Cancer Research
  55. Vitamin C in combination with inhibition of mutant IDH1 synergistically activates TET enzymes and epigenetically modulates gene silencing in colon cancer cells
    Christian Gerecke, Fabian Schumacher, Alide Berndzen, Thomas Homann, Burkhard Kleuser · 2019 · Epigenetics
  56. Genomics and Therapeutic Vulnerabilities of Primary Bone Tumors
    Katia Scotlandi, Claudia Maria Hattinger, Evelin Pellegrini, Marco Gambarotti, Massimo Serra · 2020 · Cells
  57. The Jumonji family: past, present and future of histone demethylases in cancer
    Gianluigi Franci, Alfonso Ciotta, Lucia Altucci · 2014 · BioMolecular Concepts
  58. Update on hypoxia-inducible factors and hydroxylases in oxygen regulatory pathways: from physiology to therapeutics
    Peter John Ratcliffe, Peppi Koivunen, Johanna Myllyharju, Jiannis Ragoussis, Judith V.M.G. Bovée, Ines Batinic̈‐Haberle, Claire S. Vinatier, Valérie Trichet, Florence Robriquet, Lisa Oliver et al. · 2017 · Hypoxia
  59. The role of metabolic enzymes in mesenchymal tumors and tumor syndromes: genetics, pathology, and molecular mechanisms
    Inga‐Marie Schaefer, Jason L. Hornick, Judith V.M.G. Bovée · 2018 · Laboratory Investigation
  60. Evolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations
    Michael J. Buege, Adam J. DiPippo, Courtney Denton Dinardo · 2018 · Cancers
  61. IDH1‐mutant cancer cells are sensitive to cisplatin and an IDH1‐mutant inhibitor counteracts this sensitivity
    Mohammed Khurshed, Niels Aarnoudse, Renske Hulsbos, Vashendriya V.V. Hira, Hanneke W.M. van Laarhoven, Johanna W. Wilmink, Remco Jurriaan Molenaar, Cornelis J.F. Van Noorden · 2018 · The FASEB Journal
  62. RFX5 promotes the progression of hepatocellular carcinoma through transcriptional activation of KDM4A
    Dongbo Chen, Xingwang Xie, Yangjing Zhao, Xueyan Wang, Weijia Liao, Pu Chen, Kangjian Deng, Ran Fei, Wanying Qin, Jianghua Wang et al. · 2020 · Scientific Reports
  63. The metabolic-epigenetic nexus in type 2 diabetes mellitus
    Gareth W. Davison, Rachelle E Irwin, Colum P. Walsh · 2021 · Free Radical Biology and Medicine
  64. Biological Roles and Therapeutic Applications of IDH2 Mutations in Human Cancer
    Jinxiu Guo, Ruyue Zhang, Zhe Yang, Zhenfeng Duan, De-Tao Yin, Yubing Zhou · 2021 · Frontiers in Oncology
  65. Harnessing Lactate Metabolism for Radiosensitization
    Kevin X. Liu, Emily Everdell, Sharmistha Pal, Daphne Adele Haas-Kogan, Michael Milligan · 2021 · Frontiers in Oncology
  66. 2-Oxoglutarate derivatives can selectively enhance or inhibit the activity of human oxygenases
    Yu Nakashima, Lennart Brewitz, Anthony Tumber, E. Salah, Christopher John Schofield · 2021 · Nature Communications
  67. The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer
    Yang Liu, Wei Xu, Mingxue Li, Yueying Yang, Dejuan Sun, Lidian Chen, Hua Li, Lixia Chen · 2023 · Acta Pharmaceutica Sinica B
  68. Role of 5-hydroxymethylcytosine level in diagnosis and prognosis prediction of intrahepatic cholangiocarcinoma
    Zhao‐Ru Dong, Chi Zhang, Jiabin Cai, Pengfei Zhang, Guo‐Ming Shi, Dongmei Gao, Hui‐Chuan Sun, Shuang–Jian Qiu, Jian Zhou, Ai‐Wu Ke et al. · 2014 · Tumor Biology
  69. Oncometabolic Nuclear Reprogramming of Cancer Stemness
    Javier Abel Menéndez, Bruna Corominas-Faja, Elisabet Cuyàs, María G. García, Salvador Fernández‐Arroyo, Agustín F. Fernández, Jorge Joven, Mario F. Fraga, Tomás Alarcón · 2016 · Stem Cell Reports
  70. New insights in the pathogenesis of T-cell lymphomas
    François Lemonnier, Philippe Gaulard, Laurence de Leval · 2018 · Current Opinion in Oncology
  71. Comprehensive Metabolomic Analysis of IDH1R132H Clinical Glioma Samples Reveals Suppression of β-oxidation Due to Carnitine Deficiency
    Satsuki Miyata, Kaoru Tominaga, Eiji Sakashita, Masashi Urabe, Yoshiyuki Onuki, Akira Gomi, Takashi Yamaguchi, Makiko Mieno, Hiroaki Mizukami, Akihiro Kume et al. · 2019 · Scientific Reports
  72. Inborn errors of metabolite repair
    Maria Veiga‐da‐Cunha, Emile VAN SCHAFTINGEN, Guido T. Bommer · 2019 · Journal of Inherited Metabolic Disease
  73. Is the IDH Mutation a Good Target for Chondrosarcoma Treatment?
    Elena Cojocaru, Christopher P. Wilding, Bodil Engelman, Paul H. Huang, Robin L. Jones · 2020 · Current Molecular Biology Reports
  74. Mito-Nuclear Communication in Hepatocellular Carcinoma Metabolic Rewiring
    Tommaso Mello, Irene Simeone, Andrea Galli · 2019 · Cells
  75. 5‐Hydroxymethylcytosin, die sechste Base des Genoms
    Martin Münzel, Daniel Globisch, Thomas Carell · 2011 · Angewandte Chemie
  76. Neomorphic mutations create therapeutic challenges in cancer
    Vinita Takiar, Carman Ka Man Ip, Meng Gao, Gordon Brent Mills, Lydia W.T. Cheung · 2016 · Oncogene
  77. Immunohistochemically detected IDH1R132H mutation is rare and mostly heterogeneous in prostate cancer
    Andrea Hinsch, Meta Brolund, Claudia Hube‐Magg, Martina Kluth, Ronald Simon, Christina Möller‐Koop, Guido Sauter, Stefan A. Steurer, Andreas M. Luebke, Alexander Angerer et al. · 2018 · World Journal of Urology
  78. Recent advances in the biology of tumour hypoxia with relevance to diagnostic practice and tissue‐based research
    Philip S. Macklin, Atsushi Yamamoto, Lisa Browning, Monika Hofer, Julie Adam, Christopher William Pugh · 2020 · The Journal of Pathology
  79. Interpreting new molecular genetics in myelodysplastic syndromes
    Omar Ibrahim Abdel-Wahab, María E. Figueroa · 2012 · Hematology
  80. NADP+-dependent IDH1R132 mutation and its relevance for glioma patient survival
    Nishita M S Baldewpersad Tewarie, Ilsa A. V. Burgers, Yousif Dawood, Hannah C. den Boon, Melina G.H.E. den Brok, Jet H. Klunder, Kristijn B. Koopmans, Emma Rademaker, Hans B. van den Broek, Sil M. van den Bersselaar et al. · 2013 · Medical Hypotheses
  81. Advances and challenges in understanding histone demethylase biology
    Radosław P. Nowak, Anthony Tumber, C. Johansson, Ka Hing Che, Paul E. Brennan, Dafydd R. Owen, Udo C. T. Oppermann · 2016 · Current Opinion in Chemical Biology
  82. Small molecule KDM4s inhibitors as anti-cancer agents
    Hongzhi Lin, Qihang Li, Qi Li, Jie Zhu, Kai Xuan Gu, Xueyang Jiang, Qianqian Hu, Feng Feng, Wei Qu, Yao Chen et al. · 2018 · Journal of Enzyme Inhibition and Medicinal Chemistry
  83. Rapid diagnosis of IDH1-mutated gliomas by 2-HG detection with gas chromatography mass spectrometry
    Hao Xu, Yukun Xia, Chunjie Li, Jinye Zhang, Ying Liu, Yi Wei, Zhiyong Qin, Liang Chen, Zhifeng Shi, Kai Quan et al. · 2018 · Laboratory Investigation
  84. Intergenerational trauma transmission is associated with brain metabotranscriptome remodeling and mitochondrial dysfunction
    Sammy Alhassen, Siwei Chen, Lamees Alhassen, Alvin Phan, Mohammad Khoudari, Angele De Silva, Huda Barhoosh, Zitong Wang, Chelsea Marie T. Parrocha, Emily Shapiro et al. · 2021 · Communications Biology
  85. Innovative Medicine
    Kazuwa Nakao, Nagahiro Minato, Shinji Üemoto · 2015 · Springer eBooks
  86. The Role of Ten-Eleven Translocation Proteins in Inflammation
    Christian Gerecke, Caue Egea Rodrigues, Thomas Homann, Burkhard Kleuser · 2022 · Frontiers in Immunology
  87. Radiomics, Metabolic, and Molecular MRI for Brain Tumors
    Philipp Kickingereder, Ovidiu C. Andronesi · 2018 · Seminars in Neurology
  88. Oncometabolite L‐2‐hydroxyglurate directly induces vasculogenic mimicry through PHLDB2 in renal cell carcinoma
    Huan Wang, Liya Wang, Qiming Zheng, Zeyi Lu, Yuanlei Chen, Danyang Shen, Dingwei Xue, Minxiao Jiang, Lifeng Ding, Jie Zhang et al. · 2020 · International Journal of Cancer
  89. Hypoxic adaptation of mitochondria and its impact on tumor cell function
    Martin Benej, Ioanna Papandreou, Nicholas C. Denko · 2024 · Seminars in Cancer Biology
  90. Mutations in epigenetic regulators in myelodysplastic syndromes
    Gorica Nikoloski, Bert A. van der Reijden, Joop H. Jansen · 2012 · International Journal of Hematology
  91. Somatic alterations and dysregulation of epigenetic modifiers in cancers
    Shlomzion Aumann, Omar Ibrahim Abdel-Wahab · 2014 · Biochemical and Biophysical Research Communications
  92. Small molecule epigenetic inhibitors targeted to histone lysine methyltransferases and demethylases
    Zhanxin Wang, Dinshaw J. Patel · 2013 · Quarterly Reviews of Biophysics
  93. Clinical and immunological correlates of long term survival in glioblastoma
    Bartosz Czapski, Szymon Baluszek, Christel C. Herold‐Mende, Bozena Kaminska · 2018 · Współczesna Onkologia
  94. Isocitrate dehydrogenase 1-mutated cancers are sensitive to the green tea polyphenol epigallocatechin-3-gallate
    Tom H. Peeters, Krissie Lenting, Vincent Breukels, Sanne A. M. van Lith, Corina N. A. M. van den Heuvel, Remco Jurriaan Molenaar, Arno van Rooij, Ron A. Wevers, Paul N. Span, Arend Heerschap et al. · 2019 · Cancer & Metabolism
  95. Mutant IDH1 confers resistance to energy stress in normal biliary cells through PFKP-induced aerobic glycolysis and AMPK activation
    Hiroaki Fujiwara, Keisuke Tateishi, Kento Misumi, Akimasa Hayashi, Kaori Igarashi, Hiroyuki Kato, Takuma Nakatsuka, Nobumi Suzuki, Keisuke Yamamoto, Yotaro Kudo et al. · 2019 · Scientific Reports
  96. Role of succinate dehydrogenase deficiency and oncometabolites in gastrointestinal stromal tumors
    Yue Zhao, Fei Feng, Qinghong Guo, Yuping Wang, Rui Zhao · 2020 · World Journal of Gastroenterology
  97. Discovery and Optimization of 2H-1λ2-Pyridin-2-one Inhibitors of Mutant Isocitrate Dehydrogenase 1 for the Treatment of Cancer
    Jason M. Rohde, Karavadhi Surendra, Rajan Pragani, Li Liu, Yuhong Fang, Weihe Zhang, Andrew L. McIver, Hongchao Zheng, Qingyang Liu, Mindy I. Davis et al. · 2021 · Journal of Medicinal Chemistry
  98. Inhibition of AlkB Nucleic Acid Demethylases: Promising New Epigenetic Targets
    Gemma S. Perry, Mohua Das, Esther C. Y. Woon · 2021 · Journal of Medicinal Chemistry
  99. Targeting Isocitrate Dehydrogenase (IDH) in Solid Tumors: Current Evidence and Future Perspectives
    Francesca Carosi, Elisabetta Broseghini, Laura Fabbri, Giacomo Corradi, Riccardo Gili, Valentina Forte, Roberta Roncarati, Daria Maria Filippini, Manuela Ferracin · 2024 · Cancers
  100. Epigenetic pathway targets for the treatment of disease: accelerating progress in the development of pharmacological tools: IUPHAR Review 11
    David F. Tough, Huw D. Lewis, Inmaculada Rioja, Matthew J. Lindon, Rab K. Prinjha · 2014 · British Journal of Pharmacology